Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Total Current Liabilities (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Total Current Liabilities data on record, last reported at $22.2 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 20.4% year-over-year to $22.2 million; the TTM value through Sep 2025 reached $22.2 million, up 20.4%, while the annual FY2024 figure was $16.6 million, 23.58% up from the prior year.
  • Total Current Liabilities reached $22.2 million in Q3 2025 per ABEO's latest filing, down from $34.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $41.9 million in Q2 2021 and bottomed at $7.4 million in Q1 2023.
  • Average Total Current Liabilities over 5 years is $18.4 million, with a median of $16.6 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: tumbled 69.79% in 2022, then skyrocketed 119.0% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $16.6 million in 2021, then tumbled by 53.2% to $7.8 million in 2022, then skyrocketed by 72.54% to $13.4 million in 2023, then increased by 23.58% to $16.6 million in 2024, then skyrocketed by 33.72% to $22.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $22.2 million in Q3 2025, $34.5 million in Q2 2025, and $18.0 million in Q1 2025.